

CORRIGENDUM

GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils


Nariman A B Balenga¹, Elma Aflaki², Julia Kargl¹, Wolfgang Platzer¹, Ralf Schröder³, Stefanie Blättermann³, Evi Kostenis³, Andrew J Brown⁴, Akos Heinemann¹, Maria Waldhoer¹

¹Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitätsplatz 4, Graz A-8010, Austria; ²Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria; ³Section Molecular, Cellular and Pharmacobiology, Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany; ⁴Department of Screening and Compound Profiling, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, UK

Cell Research (2011) **21**:1641. doi:10.1038/cr.2011.169; published online 3 November 2011

Correction to: *Cell Research* (2011) **21**:1452-1469. doi:10.1038/cr.2011.60; published online 5 April 2011

The authors apologize for the wrong β -actin blot in Figure 4Ai. The Figure 4Ai with the correct β -actin blot is as follows:



The authors would also like to update the current addresses for two of the authors in this corrigendum.

Nariman A B Balenga: Molecular and Signal Transduction Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

E-mail: nariman.balenga@nih.gov

Maria Waldhoer: Hagedorn Research Institute, Novo Nordisk, A/S, Niels Steensensvej 6, DK-2820 Gentofte, Denmark.

E-mail: mriw@hagedorn.dk